Rivoceranib
- Generic Name
- Rivoceranib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N5O
- CAS Number
- 811803-05-1
- Unique Ingredient Identifier
- 5S371K6132
- Background
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
- Indication
本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。
- Associated Conditions
- -
- Associated Therapies
- -
A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2022-04-18
- Lead Sponsor
- Elevar Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT05287360
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC with Portal Vein Invasion: a Randomized Trial
- Conditions
- Interventions
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 214
- Registration Number
- NCT05198609
- Locations
- 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2021-12-28
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 35
- Registration Number
- NCT05171309
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas
- Conditions
- Interventions
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 30
- Registration Number
- NCT05142865
- Locations
- 🇨🇳
Tongji Hospital，Tongji Medical College Affiliated，Huazhong University of Science ＆ Technology, Wuhan, Hubei, China
Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Feng Wang
- Target Recruit Count
- 234
- Registration Number
- NCT05049681
Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 60
- Registration Number
- NCT05029453
- Locations
- 🇨🇳
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT04985136
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2021-10-01
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 172
- Registration Number
- NCT04974944
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Wuhan University
- Target Recruit Count
- 88
- Registration Number
- NCT04878107
- Locations
- 🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
Apatinib With Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma Of The Stomach
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Peking University
- Target Recruit Count
- 41
- Registration Number
- NCT04863430
- Locations
- 🇨🇳
Beijing Cancer Hospital / Peking University Cancer Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.